J+D Forecasting collaborate with the University of Bath School of Management

19th February 2019
J+D Forecasting are advancing the future of forecasting education. We are pleased to have contributed our comprehensive forecasting training materials to the esteemed Strategy & Organisation Division of the University of Bath School of Management.  This collaboration played a pivotal role in enriching a market…
Read More

Improving Knowledge and Understanding

22nd January 2019
The gap in pharma forecasting knowledge and understanding appears to be increasing. Yet the availability of up to date pharmaceutical forecasting training is limited. Pharma forecasting is a business-critical activity, yet many clients tell us they lack confidence and that the task is time consuming…
Read More

J+D expands theHub ready for 2019

8th January 2019
J+D brought several innovations to market last year including online training, theHub, and Epi+ and Onco+ forecasting software. Onco+ was the latest innovation from the pharma forecasting company, established over 10 years ago. Sophie Adlard, Hub Lead “We have created theHub so that anyone involved…
Read More

J+D grows in the Middle East and partners with Curis Health

24th October 2018
We are pleased to announce a partnership between J+D Forecasting and Curis Health MEA, a leading healthcare consultancy based in Dubai. This partnership signifies a union of expertise, resources, and a shared commitment to delivering excellence in the healthcare industry.   About Curis Health MEA…
Read More

The First Online Pharma Forecasting Training brought to the market by J+D

18th October 2018
Following the success of J+D’s face to face pharma forecasting training workshops, they have digitalised the format. This is the first ever online pharmaceutical forecasting training course of its kind. “At J+D we love to educate, support and inject the passion we have for forecasting…
Read More

theHub is here – the place for all your forecasting needs

2nd October 2018
Today J+D is celebrating the launch of theHub. theHub is a brand-new innovation that houses everything anyone involved in forecasting could need. theHub is accessible 24/7 for people to create, build and learn about forecasting at any time any place and any pace. theHub includes…
Read More

Something beautiful in forecasting is about to happen

2nd July 2018
Introducing FC+ J+D Forecasting are very proud to announce the launch of their latest pharmaceutical forecasting innovation, FC+. Developed by J+D software experts, FC+ is set to disrupt the way pharma and biotech companies approach forecasting. A significant advancement in forecasting Say goodbye to the…
Read More

A Year of Change at J+D – new branding, products and website

25th September 2018
The ‘shape’ of J+D (previously J&D Consulting) has changed in the last 9 months with several product innovations, new branding and a new website greeting the market. Traditionally, for the last 10 years, J+D have provided Bespoke consultancy forecasting solutions for global and local affiliates.…
Read More

J+D delivers impactful forecasting training at EphMRA 2016 Conference

17th July 2016
We were delighted to be a part of EphMRA’s Flagship Annual Conference this year in Frankfurt. As a thought leader in Forecasting, David James (CEO of J+D) is always pleased to offer advice and support to others in the Pharma Industry regarding the importance of…
Read More

David Baker Joins J+D from Fresenius Kabi

1st October 2018
David Baker joins J+D as a Business Consultant to support clients with ‘Bespoke’ complex model development, FC+ ongoing software development and FC365, Sharepoint and PowerBI technologies. David is a fully trained Pharmacist with academic, hospital and community experience. In his previous role for Fresenius Kabi,…
Read More

The Fundamental Pillars that Support Good Forecasting

21st June 2017
The Context Here at J+D we create 100’s of strategic forecasting and operational planning models for many of the largest pharmaceutical companies year on year. These figures have increased consistently, certainly in the last 5-7 years; as scrutiny from pharmaceutical investors puts increasing pressure on revenue…
Read More